糖尿病患者感染SARS-CoV-2后能产生持久的中和抗体
该研究从509例确诊COVID-19肺炎患者中随机选取150例,采用慢病毒载体中和试验检测中和抗体,分析糖尿病或高血糖对中和抗体动力学和持久性的影响。结果显示,糖尿病和高血糖不影响中和抗体反应,且入院时中和抗体阳性与死亡率降低相关。
要点
- 糖尿病和高血糖不影响SARS-CoV-2中和抗体的动力学和持久性。
- 入院时中和抗体阳性与糖尿病和非糖尿病患者死亡率降低均相关。
- 研究结果为将糖尿病患者纳入SARS-CoV-2疫苗接种早期阶段提供了依据。
核心结论
- 糖尿病和高血糖不影响SARS-CoV-2中和抗体反应的动力学和持久性。
研究设计与样本
- 从509例确诊COVID-19肺炎患者中随机选取150例,使用慢病毒载体中和试验检测中和抗体,按糖尿病或高血糖状态分析住院时及出院后1、3、6个月随访的中和抗体反应。
主要发现
- 150例中40例(26.6%)有糖尿病。
- 糖尿病(HR 8.9,P < .001)、血糖水平(HR 1.25 × 1.1 mmol/L,P < .001)和血糖变异性(HR 1.17 × 0.6 mmol/L,P < .001)与死亡风险增加独立相关。
- 糖尿病患者的中和抗体动力学和程度与非糖尿病患者重叠,且在不同血糖水平间相似,并与针对SARS-CoV-2刺突蛋白的体液反应相关。
- 入院时中和抗体阳性与死亡率降低相关:糖尿病患者HR 0.28,P = .046;非糖尿病患者HR 0.26,P = .030。
- 中和抗体反应的持久性不受糖尿病影响。
临床怎么用
- 糖尿病和高血糖患者感染SARS-CoV-2后仍能产生持久的中和抗体,支持将其纳入疫苗接种早期阶段。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Demonstrating the ability to mount a neutralizing antibody response to SARS-CoV-2 in the presence of diabetes is crucial to understand COVID-19 pathogenesis, reinfection potential, and vaccine development. OBJECTIVE: The aim of this study was to characterize the kinetics and durability of neutralizing antibody (Nab) response against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the presence of hyperglycemia. METHODS: Using a lentiviral vector-based SARS-CoV-2 neutralization assay to measure Nabs, we characterized 150 patients randomly selected from a cohort of 509 patients with confirmed COVID-19 pneumonia. We analyzed Nab response according to the presence of diabetes or hyperglycemia, at the time of hospitalization and during the postdischarge follow-up: 1-, 3-, and 6-month outpatient visits. RESULTS: Among 150 randomly selected patients 40 (26.6%) had diabetes. Diabetes (hazard ratio [HR] 8.9, P < .001), glucose levels (HR 1.25 × 1.1 mmol/L, P < .001), and glucose variability (HR 1.17 × 0.6 mmol/L, P < .001) were independently associated with an increased risk of mortality. The neutralizing activity of SARS-CoV-2 antibodies in patients with diabetes was superimposable, as for kinetics and extent, to that of patients without diabetes. It was similar across glucose levels and correlated with the humoral response against the SARS-CoV-2 spike protein. Positivity for Nabs at the time of hospital admission conferred protection on mortality, both in the presence (HR 0.28, P = .046) or absence of diabetes (HR 0.26, P = .030). The longevity of the Nab response was not affected by diabetes. CONCLUSION: Diabetes and hyperglycemia do not affect the kinetics and durability of the neutralizing antibody response to SARS-CoV-2. These findings provide the rational to include patients with diabetes in the early phase of the vaccination campaign against SARS-CoV-2.
引用
- Dispinseri S, Lampasona V, Secchi M, et al. Robust Neutralizing Antibodies to SARS-CoV-2 Develop and Persist in Subjects with Diabetes and COVID-19 Pneumonia. J Clin Endocrinol Metab. 2021. PMID: 33513242. doi:10.1210/clinem/dgab055
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。